BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 7765323)

  • 1. Topoisomerase II in multiple drug resistance.
    Hofmann GA; Mattern MR
    Cytotechnology; 1993; 12(1-3):137-54. PubMed ID: 7765323
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of multidrug resistance by tyrosine-kinase inhibitors in a non-P-glycoprotein-mediated multidrug-resistant cell line.
    Takeda Y; Nishio K; Niitani H; Saijo N
    Int J Cancer; 1994 Apr; 57(2):229-39. PubMed ID: 7908894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flow cytometric assays of anticancer drug resistance.
    Hedley DW
    Ann N Y Acad Sci; 1993 Mar; 677():341-53. PubMed ID: 8098593
    [No Abstract]   [Full Text] [Related]  

  • 5. [Poisons of DNA topoisomerases I and II].
    Charcosset JY; Soues S; Laval F
    Bull Cancer; 1993 Nov; 80(11):923-54. PubMed ID: 8081034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mutations of human topoisomerase II alpha affecting multidrug resistance and sensitivity.
    Mao Y; Yu C; Hsieh TS; Nitiss JL; Liu AA; Wang H; Liu LF
    Biochemistry; 1999 Aug; 38(33):10793-800. PubMed ID: 10451375
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype.
    Eijdems EW; Borst P; Jongsma AP; de Jong S; de Vries EG; van Groenigen M; Versantvoort CH; Nieuwint AW; Baas F
    Proc Natl Acad Sci U S A; 1992 Apr; 89(8):3498-502. PubMed ID: 1348862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of an unusual mutant of human melanoma cells resistant to anticancer drugs that inhibit topoisomerase II.
    Campain JA; Padmanabhan R; Hwang J; Gottesman MM; Pastan I
    J Cell Physiol; 1993 May; 155(2):414-25. PubMed ID: 8097746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Resistance to inhibitors of DNA topoisomerases.
    Sullivan DM; Ross WE
    Cancer Treat Res; 1991; 57():57-99. PubMed ID: 1686723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance mechanisms to topoisomerase poisons: the application of cell culture methods.
    Baguley BC; Finlay GJ; Ching LM
    Oncol Res; 1992; 4(7):267-74. PubMed ID: 1360275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias.
    Gekeler V; Frese G; Noller A; Handgretinger R; Wilisch A; Schmidt H; Muller CP; Dopfer R; Klingebiel T; Diddens H
    Br J Cancer; 1992 Sep; 66(3):507-17. PubMed ID: 1355660
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical implications of multidrug resistance to chemotherapy.
    de Vries EG; Pinedo HM
    Cancer Treat Res; 1991; 57():171-86. PubMed ID: 1686716
    [No Abstract]   [Full Text] [Related]  

  • 14. Anti-tumour activities of a new benzo[c]phenanthridine agent, 2,3-(methylenedioxy)-5-methyl-7-hydroxy-8-methoxybenzo[c]phena nthridini um hydrogensulphate dihydrate (NK109), against several drug-resistant human tumour cell lines.
    Kanzawa F; Nishio K; Ishida T; Fukuda M; Kurokawa H; Fukumoto H; Nomoto Y; Fukuoka K; Bojanowski K; Saijo N
    Br J Cancer; 1997; 76(5):571-81. PubMed ID: 9303354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased DNA topoisomerase II in daunorubicin-resistant Ehrlich ascites tumor cells.
    Friche E; Danks MK; Schmidt CA; Beck WT
    Cancer Res; 1991 Aug; 51(16):4213-8. PubMed ID: 1678312
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circumvention of atypical multidrug resistance with tumor necrosis factor.
    Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
    Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Involvement of DNA topoisomerase II in the selective resistance of a mammalian cell mutant to DNA minor groove ligands: ligand-induced DNA-protein crosslinking and responses to topoisomerase poisons.
    Smith PJ; Bell SM; Dee A; Sykes H
    Carcinogenesis; 1990 Apr; 11(4):659-65. PubMed ID: 2157558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II.
    Mistry P; Stewart AJ; Dangerfield W; Baker M; Liddle C; Bootle D; Kofler B; Laurie D; Denny WA; Baguley B; Charlton PA
    Anticancer Drugs; 2002 Jan; 13(1):15-28. PubMed ID: 11914637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes.
    Mestdagh N; Pommery N; Saucier JM; Hecquet B; Fournier C; Slomianny C; Teissier E; Hénichart JP
    Anticancer Res; 1994; 14(3A):869-74. PubMed ID: 7915509
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.